Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jean-Claude

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Molecular Cancer Research : MCR|January 26, 2011
MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1Ying Huang, Zakaria Rachid, Bertrand J Jean-Claude
Biochemical Pharmacology|March 10, 2004
The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41Stephanie L Matheson, Fouad Brahimi, Bertrand J Jean-Claude
Journal of Signal Transduction|April 24, 2012
The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial MimicriesHeather L Watt, Zakaria Rachid, Bertrand J Jean-Claude
The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategyS L Matheson, J McNamee, B J Jean-Claude
Journal of Neuro-Oncology|May 15, 2010
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targetingH L Watt, Z Rachid, B J Jean-Claude
Molecules (Basel, Switzerland)|January 11, 2024
Molecular Profiling of Peanut under Raw, Roasting, and Autoclaving Conditions Using High-Resolution Magic Angle Spinning and Solution <sup>1</sup>H NMR SpectroscopyCasey G Cohen, Bruce D Mazer, Bertrand J Jean-Claude
Cancer Chemotherapy and Pharmacology|December 24, 2002
Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41Stephanie L Matheson, James P McNamee, Bertrand J Jean-Claude
Journal of Medicinal Chemistry|December 3, 2003
Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting conceptRanjita Banerjee, Zakaria Rachid, James McNamee, et al.
Breast Cancer Research and Treatment|September 15, 2011
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of XelodaMaria Ait-Tihyaty, Zakaria Rachid, Catalin Mihalcioiu, et al.
Oncotarget|November 13, 2018
Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O<sup>6</sup>-methylguanine-DNA methyltransferase with a double arm hybrid moleculeMartin Rupp, Zhor Senhaji Mouhri, Christopher Williams, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Molecular Cancer Research : MCR|January 26, 2011
MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1Ying Huang, Zakaria Rachid, Bertrand J Jean-Claude
Biochemical Pharmacology|March 10, 2004
The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41Stephanie L Matheson, Fouad Brahimi, Bertrand J Jean-Claude
Journal of Signal Transduction|April 24, 2012
The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial MimicriesHeather L Watt, Zakaria Rachid, Bertrand J Jean-Claude
The Journal of Pharmacology and Experimental Therapeutics|February 22, 2001
Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategyS L Matheson, J McNamee, B J Jean-Claude
Journal of Neuro-Oncology|May 15, 2010
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targetingH L Watt, Z Rachid, B J Jean-Claude
Molecules (Basel, Switzerland)|January 11, 2024
Molecular Profiling of Peanut under Raw, Roasting, and Autoclaving Conditions Using High-Resolution Magic Angle Spinning and Solution <sup>1</sup>H NMR SpectroscopyCasey G Cohen, Bruce D Mazer, Bertrand J Jean-Claude
Cancer Chemotherapy and Pharmacology|December 24, 2002
Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41Stephanie L Matheson, James P McNamee, Bertrand J Jean-Claude
Journal of Medicinal Chemistry|December 3, 2003
Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting conceptRanjita Banerjee, Zakaria Rachid, James McNamee, et al.
Breast Cancer Research and Treatment|September 15, 2011
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of XelodaMaria Ait-Tihyaty, Zakaria Rachid, Catalin Mihalcioiu, et al.
Oncotarget|November 13, 2018
Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O<sup>6</sup>-methylguanine-DNA methyltransferase with a double arm hybrid moleculeMartin Rupp, Zhor Senhaji Mouhri, Christopher Williams, et al.
Pageof 8